PDCD1 and melanoma: Similarly, RELATIVITY-047 (NCT03470922) is a randomized, double-blind, phase II/III clinical trial that assessed the efficacy and safety of relatlimab (LAG3 antibody) combined with nivolumab (PD-1 antibody) versus nivolumab monotherapy in previously untreated metastatic or unresectable melanoma.